Core Viewpoint - The company Chongqing Pharmaceutical Holdings (重药控股) has received the clinical trial approval notice for its drug, Prasugrel Hydrochloride Tablets, from the National Medical Products Administration (NMPA) of China, indicating progress in its drug development process [1] Group 1 - The company announced on September 12 that it will soon commence clinical trials for Prasugrel Hydrochloride Tablets following the receipt of the approval notice [1] - According to Chinese drug registration laws and regulations, the drug must undergo clinical trials and receive further review and approval from the NMPA before it can be manufactured and marketed [1] - The drug development process is lengthy and involves multiple stages, making it susceptible to various uncertainties [1]

Company Overview - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has received the Clinical Trial Approval Notice from the National Medical Products Administration for the drug named Prasugrel Hydrochloride Tablets [1] - Zhongyao Holdings reported a market capitalization of 9 billion yuan [1] Revenue Composition - For the first half of 2025, the revenue composition of Zhongyao Holdings is as follows: 94.81% from pharmaceutical wholesale, 4.73% from pharmaceutical retail, and 0.46% from other businesses [1]

Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has received approval from the National Medical Products Administration to conduct clinical trials for its drug, which is currently not available in China [1] Company Summary - Zhongyao Holdings' subsidiary, Chongqing Pharmaceutical, is set to initiate clinical trials for the drug, which is a third-generation platelet aggregation inhibitor [1] - The drug, Prasugrel Hydrochloride Tablets, is indicated for preventing thrombus formation in patients undergoing percutaneous coronary intervention for acute coronary syndrome, stable angina, and old myocardial infarction [1] Industry Summary - The drug is already marketed in over 70 countries and regions globally, indicating its established presence in the international pharmaceutical market [1]

Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has received approval from the National Medical Products Administration for clinical trials of Prasugrel Hydrochloride Tablets, marking a significant step in expanding its product portfolio in the cardiovascular drug market [1]. Company Summary - Zhongyao Holdings' subsidiary, Chongqing Pharmaceutical, has been granted a clinical trial approval for Prasugrel Hydrochloride Tablets by the National Medical Products Administration [1]. - Prasugrel Hydrochloride is a third-generation drug that inhibits ADP-induced platelet aggregation, aimed at preventing thrombus formation in patients undergoing percutaneous coronary intervention for acute coronary syndrome, stable angina, and old myocardial infarction [1]. - The original developer of Prasugrel is Daiichi Sankyo Co., Ltd., and the drug is currently available in over 70 countries and regions worldwide, although it has not yet been launched in China [1].

Core Viewpoint - Zhongyao Holdings (000950) announced that its subsidiary, Zhongyao Co., has received the clinical trial approval notice from the National Medical Products Administration for the drug Prasugrel Hydrochloride Tablets, which will soon commence clinical trials [1] Company Summary - The drug is indicated for the prevention of thrombus formation in patients undergoing percutaneous coronary intervention for acute coronary syndrome, stable angina, and old myocardial infarction [1]

Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Chongqing Pharmaceutical Holdings, has received the Clinical Trial Approval Notice from the National Medical Products Administration for the drug Prasugrel Hydrochloride Tablets, which is intended for clinical trials [1] Group 1 - The drug Prasugrel Hydrochloride Tablets is a third-generation inhibitor of ADP-induced platelet aggregation [1] - The drug is indicated for the prevention of thrombus formation in patients with acute coronary syndrome after percutaneous coronary intervention, stable angina, and old myocardial infarction [1]